T Pina1, F Genre1, R Lopez-Mejias1, S Armesto2, B Ubilla1, V Mijares1, T Dierssen-Sotos3,4, M A Gonzalez-Lopez2, M C Gonzalez-Vela5, R Blanco1, J L Hernández6, J Llorca3,4, M A Gonzalez-Gay1. 1. Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. 2. Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. 3. Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Santander, Spain. 4. CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain. 5. Pathology Division, Hospital Universitario Marqués de Valdecilla, University of Cantabria, Santander, Spain. 6. Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Abstract
BACKGROUND: Altered secretion patterns of proinflammatory adipokines may influence the increased risk of cardiovascular mortality observed in patients with chronic inflammatory diseases. OBJECTIVE: To determine whether two adipokines, leptin and resistin, correlate with metabolic syndrome features and disease severity in psoriatic patients who underwent anti-TNF-α therapy. METHODS: Prospective study of consecutive non-diabetic patients with moderate-to-severe psoriasis who completed 6 months of therapy with anti-TNF-α- adalimumab. Patients with kidney disease, hypertension or body mass index ≥35 Kg/m(2) were excluded. Metabolic and clinical evaluation was performed at the onset of anti-TNF-α treatment and at month 6. RESULTS: Twenty-nine patients were assessed. A correlation between adiposity and leptin was observed (waist circumference and leptin levels after 6 months of therapy: r = 0.43; P = 0.030). Leptin concentration also correlated with blood pressure before adalimumab onset (systolic: r = 0.48; P = 0.013 and diastolic blood pressure: r = 0.50; P = 0.010 ). A marginally significant negative correlation between insulin sensitivity (QUICKI) and leptin levels was also observed. CRP levels correlated with leptin prior to the onset of adalimumab (r = 0.45; P = 0.020) and with resistin both before (r = 0.45; P = 0.020) and after 6 months of therapy (r = 0.55; P = 0.004). A positive association between parameters of disease activity such as BSA (r = 0.60; P = 0.001) and PASI (r = 0.63; P = 0.001) prior to the onset of adalimumab therapy and resistin concentrations was also disclosed. No significant changes in leptin and resistin concentrations following the 6-month treatment with adalimumab were seen. CONCLUSION: In patients with moderate-to-severe psoriasis leptin correlates with metabolic syndrome features and inflammation whereas resistin correlate with inflammation and disease severity.
BACKGROUND: Altered secretion patterns of proinflammatory adipokines may influence the increased risk of cardiovascular mortality observed in patients with chronic inflammatory diseases. OBJECTIVE: To determine whether two adipokines, leptin and resistin, correlate with metabolic syndrome features and disease severity in psoriaticpatients who underwent anti-TNF-α therapy. METHODS: Prospective study of consecutive non-diabeticpatients with moderate-to-severe psoriasis who completed 6 months of therapy with anti-TNF-α- adalimumab. Patients with kidney disease, hypertension or body mass index ≥35 Kg/m(2) were excluded. Metabolic and clinical evaluation was performed at the onset of anti-TNF-α treatment and at month 6. RESULTS: Twenty-nine patients were assessed. A correlation between adiposity and leptin was observed (waist circumference and leptin levels after 6 months of therapy: r = 0.43; P = 0.030). Leptin concentration also correlated with blood pressure before adalimumab onset (systolic: r = 0.48; P = 0.013 and diastolic blood pressure: r = 0.50; P = 0.010 ). A marginally significant negative correlation between insulin sensitivity (QUICKI) and leptin levels was also observed. CRP levels correlated with leptin prior to the onset of adalimumab (r = 0.45; P = 0.020) and with resistin both before (r = 0.45; P = 0.020) and after 6 months of therapy (r = 0.55; P = 0.004). A positive association between parameters of disease activity such as BSA (r = 0.60; P = 0.001) and PASI (r = 0.63; P = 0.001) prior to the onset of adalimumab therapy and resistin concentrations was also disclosed. No significant changes in leptin and resistin concentrations following the 6-month treatment with adalimumab were seen. CONCLUSION: In patients with moderate-to-severe psoriasis leptin correlates with metabolic syndrome features and inflammation whereas resistin correlate with inflammation and disease severity.
Authors: Divya Seth; Alexa N Ehlert; Jackelyn B Golden; Giovanni Damiani; Thomas S McCormick; Mark J Cameron; Kevin D Cooper Journal: J Invest Dermatol Date: 2019-11-15 Impact factor: 8.551
Authors: Laura Gonzalez-Lopez; Nicte S Fajardo-Robledo; A Miriam Saldaña-Cruz; Inocente V Moreno-Sandoval; David Bonilla-Lara; Soraya Zavaleta-Muñiz; Arnulfo Hernan Nava-Zavala; Paulina Hernandez-Cuervo; Alberto Rocha-Muñoz; Norma Alejandra Rodriguez-Jimenez; Maria L Vazquez-Villegas; J Francisco Muñoz-Valle; Mario Salazar-Paramo; Ernesto G Cardona-Muñoz; Jorge I Gamez-Nava Journal: J Int Med Res Date: 2017-05-23 Impact factor: 1.671
Authors: Nádia Couto Bavoso; Jackson Machado Pinto; Maria Marta Sarquis Soares; Michelle Dos Santos Diniz; Antônio Lúcio Teixeira Júnior Journal: An Bras Dermatol Date: 2019-05-09 Impact factor: 1.896